Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00386373 · ClinicalTrials.gov registry record · NA
Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients
A NA study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT00386373: Completed NA study, sponsored by M.D. Anderson Cancer Center.
NCT00386373 is a NA study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00386373, a NA study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
Primary Objective: 1\. To assess the safety and toxicity of imatinib mesylate when given to patients with Ph (+) CML , ALL or AML within the first 100 days following allogeneic bone marrow or stem cell transplantation. Secondary Objectives: 1. To identify any clinically significant drug interactions with imatinib in the post-transplant setting. 2. To develop specific monitoring parameters for imatinib use when utilized in the early post-BMT setting. 3. To record one-year survival data in this patient cohort to assess any effect of early imatinib administration on this endpoint.
Interventions
- DRUG Imatinib Mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2003-08 |
| Est. Completion | 2007-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00386373
The ClinicalTrials.gov registry entry for NCT00386373 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Imatinib Mesylate is the first listed.
NCT00386373 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00386373 about?
NCT00386373 is a clinical study titled "Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients". Primary Objective: 1\. To assess the safety and toxicity of imatinib mesylate when given to patients with Ph (+) CML , ALL or AML within the first 100 days following allogeneic bone marrow or stem cell transplantation. Secondary Objectives: 1. To identify any clinically significant drug interacti...
What is the current status of trial NCT00386373?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2003-08. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00386373?
The interventions under investigation include: Imatinib Mesylate (DRUG).
Who is sponsoring clinical trial NCT00386373?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.